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E-mail address: nhattori@juntendo.ac.jp (N. HattorMutations in parkin gene are responsible for autosomal recessive Parkinson’s disease (ARPD) and
its loss-of-function is assumed to affect parkin ubiquitin ligase activity. Accumulation of its sub-
strate may induce dopaminergic neurodegeneration in the substantia nigra (SN) of ARPD. Here,
we show that parkin interacts with programmed cell death-2 isoform 1 (PDCD2-1) and promotes
its ubiquitination. Furthermore, accumulation of PDCD2-1 was found in the SN of ARPD as well
as in sporadic PD, suggesting that common failure of the ubiquitin–proteasome system is associated
with neuronal death in both ARPD and sporadic PD.
Structured summary:
MINT-6805975, MINT-6806032, MINT-6806051, MINT-6806070: PDCD2 (uniprotkb:Q16342) physically
interacts (MI:0218) with Parkin (uniprotkb:O60260) by anti tag coimmunoprecipitation (MI:0007)
MINT-6805947: Parkin (uniprotkb:O60260) physically interacts (MI:0218) with PDCD2 (uni-
protkb:Q16342) by two hybrid (MI:0018)
MINT-6806000: PDCD2 (uniprotkb:Q16342) physically interacts (MI:0218) with ubiquitin (uni-
protkb:P62988) by anti tag coimmunoprecipitation (MI:0007)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mutations in the parkin gene are linked to autosomal recessive
Parkinson’s disease (ARPD) [1]. Parkin functions as an E3 ubiquitin
(Ub) ligase in the ubiquitin–proteasome system (UPS) [2], which
maintains intracellular protein quality. The E3 Ub ligase attaches
Ub to speciﬁc substrate(s), as well as activates E1 and conjugating
E2enzymes. Polyubiquitinatedproteins aredegradedby the26S pro-
teasome. Homozygousmutations of the parkin gene result in loss-of-
function and result in failure of the UPS. In this context, degeneration
of dopaminergic neurons in the substantia nigra (SN) of ARPD is pre-
sumed to be induced by accumulation of protein substrate(s). Thus,
identiﬁcation of the substrate(s) for parkin is important for under-
standing the mechanism of neurodegeneration of ARPD.
Programmed cell death-2 (PDCD2) protein was isolated from a
human fetal lung cDNA library and characterized as highly homol-
ogous to Rp-8, a protein associated with apoptosis [3–5]. PDCD2
exists in two isoforms [6]. The PDCD2 isoform 1 (PDCD2-1) com-chemical Societies. Published by E
i).prises 344 amino acids residues containing the MYND zinc-ﬁnger
domain [4,6]. In present study, we found that parkin interacts with
PDCD2-1 and controls its degradation. We also demonstrated high
levels of PDCD2-1 in the SN of patients with ARPD and those with
sporadic Parkinson’s disease (sPD).
2. Materials and methods
2.1. Yeast two-hybrid screening
Theparkinubl-linker (1-238) cDNAwas linked to the cDNA for the
GAL4-DNA binding domain in pGBD-ubl-linker, and yeast PJ69-2A
cellswere transformedwith pGBD-ubl-linker, and subsequentlywith
the library of SH-SY5Y cDNAs fused to the cDNA for the GAL4 activa-
tion domain (GAL4AD). The transformed yeast were selected and
conﬁrmed as described by themanufacturer (Clontech, Shiga, Japan).
2.2. Plasmids and antibodies
The full-length and mutant parkins were cloned into 3XMyc-
pcDNA3.1(+) vector at the BamHI site. Mutagenesis to introducelsevier B.V. All rights reserved.
522 J. Fukae et al. / FEBS Letters 583 (2009) 521–525point mutations was performed using the QuikChange Site-Direc-
ted Mutagenesis Kit (Stratagene, La Jolla, CA). The pCMV/3XFLAG-
PDCD2-1 was prepared by polymerase chain reaction (PCR) using
appropriately designed primers with restriction site (BamHI). The
PCR product was inserted into the p3XFLAG-CMVTM vector
(Sigma–Aldrich, St. Louis, MO). HA-Ub was a kind gift from Prof.
Keiji Tanaka (Tokyo Metropolitan Institute of Medical Science,
Tokyo). Rabbit polyclonal PDCD2 antibody was kindly provided
by Prof. Philip A. Sharp (Massachusetts Institute of Technology,
Cambridge, MA) [7]. Rabbit polyclonal anti-parkin and mouse
monoclonal GAPDH antibodies were obtained from Cell Signaling
Technology (Beverly, MA) and Chemicon (Temecula, CA), respec-
tively. Monoclonal (9E10), horseradish peroxidase (HRP)-conju-
gated monoclonal (9E10), and polyclonal (A-14) anti-Myc,
HRP-conjugated anti-FLAG (M2), biotin-conjugated anti-HA
(3F10) antibodies were purchased from Santa Cruz biotechnology
(Santa Cruz, CA), Sigma–Aldrich, and Roche (Mannheim, Germany),
respectively.
2.3. Cell culture and transfection
COS1 cells were maintained in Dulbecco’s modiﬁed Eagle med-
ium (DMEM) supplemented with 10% fetal bovine serum, penicillin
G (100 units/ml), and streptomycin (100 lg/ml) at 37 C under 5%
CO2. COS1 cells were transiently transfected with expression vec-
tors using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according
to the protocol supplied by the manufacturer.
2.4. Immunoprecipitation (IP) and western blotting
Twenty-four hours after transfection, the cells were washed
with phosphate-buffered saline (PBS) and then lysed on ice-cold ly-
sis buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.5% NP-40, and
10% glycerol) containing protease inhibitor (Complete Mini EDTA-
free, Roche Diagnostics, Penzberg, Germany) for 20 min. Lysates
were centrifuged at 4 C at 15000 rpm. The protein concentration
in the supernatant was determined using the DC protein assay kit
(Bio-Rad, Hercules, CA). The supernatant fractions were incubated
with the primary antibodies and then treated with protein G
sepharose 4 fast ﬂow (Amersham, Sweden). Immunoprecipitates
were washed three times with lysis buffer then boiled in 3X SDS
loading buffer (30 ll) for 5 min. Each sample (10 ll) was separated
by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE). The separated proteinswere transferred onto a polyvi-
nylidene diﬂuoridemicroporousmembrane (Bio-Rad, Hercules, CA)
using transfer buffer (40 mM CAPS, 30 mM Tris, and 15% MeOH).
The transferred membrane was blocked with 5% skim milk and
incubated overnight with the primary antibody at 4 C. After incu-
bationwith HRP-conjugated secondary antibodies, the reactionwas
visualized using a chemiluminescence reagent (ECL-plus, Amer-
sham). The intensity of the signal was analyzed by LAS-1000plus
(Fuji ﬁlm, Tokyo).Table 1
Clinical summary of the subjects included in the study.
Case Diagnosis Age Sex Duration Mutation
1 Control 45 Female – –
2 Control 57 Male – –
3 Control 70 Female – –
4 sPD 66 Male 10 –
5 sPD 81 Female 13 –
6 sPD 62 Male 12 –
7 ARPD 63 Male 30 Exon 3 deletion
8 ARPD 68 Male 35 Exon 3 deletion
9 ARPD 62 Male 38 Exon 4 deletion2.5. Ubiquitination assay
COS1 cells were transfected with 3XMyc-parkin, 3XFLAG-
PDCD2-1, and HA-Ub in various combinations. After 24 h, the cells
were incubated in a medium with 50 lMMG132 (Peptide Institute
Inc., Osaka, Japan) for additional 30 min. The cell lysate was
immunoprecipitated with anti-FLAG M2 afﬁnity gel (Sigma) and
products were analyzed with biotin-conjugated anti-HA, HRP-con-
jugated anti-FLAG, and HRP-conjugated anti-Myc antibodies.
2.6. Brain samples
Fresh frozen brains were obtained from the Department of Neu-
rology, Juntendo University School of Medicine. The subjects were
three patients with ARPD, three with sPD, and three control sub-
jects. Table 1 provides a summary of the clinical proﬁle of the sub-
jects. The diagnosis was conﬁrmed by neuropathological
examination of the brain tissues as sPD, and excluding neurode-
generative disorders in control subjects. Gene analysis of parkin
was preformed as reported previously [1]. The study protocol
was approved by the Human Ethics Review Committee of Juntendo
University School of Medicine. Approximately, 0.5 g of frozen mid-
brain were placed into 3.5 ml ice-cold homogenisation buffer [DTT,
50 mM Tris–HCl (pH 7.4), 0.1% SDS, 1% Triton X 100, and 1% sodium
deoxycholate] and homogenized in the presence of a mixture of
protease inhibitors (Complete Mini EDTA-free). The protein con-
centration in each sample was determined using the DC protein as-
say kit (Bio-Rad).3. Results and discussion
3.1. Identiﬁcation of PDCD2-1 as a parkin-binding protein
To identify parkin-binding protein, we screened the SHSY-5Y
cDNA library using the ubl-linker parkin by the yeast two-hybrid
method. PDCD2-1 was isolated as a potential clone that can inter-
act with parkin (data not shown). Co-immunoprecipitation analy-
sis was performed to conﬁrm the interaction between parkin and
PDCD2-1. The 3XFLAG-PDCD2-1 was co-transfected with either
3XMyc-parkin or 3XMyc control plasmid into COS1 cells. After lysis
of the transfected cells, the supernatant (1 mg protein) was pulled-
down with anti-Myc antibody (A-14). Immunoprecipitates were
boiled in 3XSDS loading buffer (30 ll) and then each sample
(10 ll) was subjected to SDS–PAGE, followed by western blotting
with HRP-conjugated anti-FLAG antibody. The 3XFLAG-PDCD2-1
band was only detected in the sample with 3XMyc-parkin, but
not in the 3XMyc plasmid (Fig. 1A). When co-immunoprecipitation
was performed in reverse with anti-FLAG M2 afﬁnity gel, only the
3XMyc-parkin band was noted in protein extracts with 3XFLAG-
PDCD2-1 (Fig. 1B). These results suggest that wild parkin interacts
with PDCD2-1.
3.2. PDCD2-1 binds to parkin at two sites
Parkin is a 465-amino acid protein, consisting of Ub-like domain
(UBL) in the N-terminal and two RING ﬁnger motifs towards the C-
terminal. Between the two RINGs, there is an in-between-RING
(IBR) structure comprising a RING-box (Fig. 1C). To investigate
the PDCD2-1 binding site(s) of parkin, we constructed various
truncated and point mutants of parkin tagged with 3XMyc
(Fig. 1C). Various mutants of 3XMyc-parkin and 3XFLAG-PDCD2-
1 were co-transfected into COS1 cells. The supernatant (1 mg
protein) was then immunoprecipitated with anti-Myc antibody
(A-14), and each sample (10 ll) was subsequently subjected to
SDS–PAGE, and western blotting with HRP-conjugated anti-FLAG
Fig. 1. Parkin interacts with PDCD2-1. (A) Lysates (1 mg protein) from COS1 cells co-transfected with 3XMyc-parkin and 3XFLAG-PDCD2-1 were subjected to
immunoprecipitation (IP) with anti-Myc antibody followed by western blot analysis with HRP-conjugated anti-FLAG and anti-Myc antibodies. To conﬁrm proper expression
level of the transiently transfected protein, input lysates were also analyzed by western blotting with HRP-conjugated anti-FLAG and anti-Myc antibodies. (B) In reverse
analysis, lysates (1 mg protein) from COS1 cells co-transfected with 3XMyc-parkin and 3XFLAG-PDCD2-1 were subjected to immunoprecipitation with anti-FLAG M2 afﬁnity
gel followed by Western blotting with HRP-conjugated anti-FLAG and anti-Myc antibodies. Input lysates were also analyzed by western blotting with HRP-conjugated anti-
FLAG and anti-Myc antibodies. (C) The structure of parkin protein. Schematic representation of wild-type and various mutant parkins. UBL: Ub-like domain; IBR: inbetween
RING structure. (D) Interaction between mutant parkin and PDCD2-1. Lysates (1 mg protein) from COS1 cells co-transfected with various 3XMyc tagged parkin domain
constructs or control plasmid, together with 3XFLAG-PDCD2-1, were subjected to IP with anti-Myc antibody. IP products and input lysates were analyzed by western blotting
with HRP-conjugated anti-FLAG and anti-Myc antibodies.
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act with PDCD2-1 (Fig. 1D, lane 3), suggesting that the UBL domain
is necessary for such interaction. Furthermore, PDCD2-1 interacted
with the RING-box domain (Fig. 1D, lane 5). However, in the pres-Fig. 2. Parkin ubiquitinates PDCD2-1. COS1 cells transfected with 3XFLAG-PDCD2-1, 3X
protein) were immunoprecipitated with anti-FLAG M2 afﬁnity gel. The immunoprecipitat
HA (A), HRP-conjugated anti-FLAG (B) and HRP-conjugated anti-Myc (C) antibodies. T
arrowheads indicate ubiquitination of PDCD2-1.ence of the LINKER domain, no interaction was noted between
UBL-domain-negative parkin and RING-box domain as evident by
the similarity of the amount of FLAG in lane 2 to that in lane 4
(Fig. 1D). Thus, the linker domain may structurally block the bind-Myc-parkin, and HA-Ub, were treated with MG132 for 30 min, and lysates (2 mg
ed products of the ubiquitination assays were detected with biotin-conjugated anti-
he ubiquitination of PDCD2-1 was promoted with transfection of parkin. White
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tion within the RING-box such as T240R and T415N, showed re-
duced binding to PDCD2-1 (Fig. 1D).
3.3. Ubiquitination and degeneration of PDCD2-1 are promoted by
parkin
Next, we used the ubiquitination assay to determine whether
PDCD2-1 is a substrate of parkin. COS1 cells were co-transfected
with various combinations of 3XFLAG-PDCD2-1, 3XMyc-parkin,
and HA-Ub. After treatment of cells with MG132 for 30 min, they
were lysed and each supernatant (2 mg protein) was immunopre-
cipitated with anti-FLAG M2 afﬁnity gel. Immunoprecipitates were
boiled in 3XSDS loading buffer (30 ll) and then each sample (10 ll)
was subjected to SDS–PAGE, followed by western blotting with
biotin-conjugated anti-HA, HRP-conjugated anti-FLAG, and HRP-
conjugated anti-Myc antibodies. Ubiquitination of PDCD2-1 was
detected by western blotting with biotin-conjugated anti-HA and
HRP-conjugated FLAG antibodies. As shown in Fig. 2A–C, ubiquiti-
nation of PDCD2-1 was promoted by transfection of 3XMyc-parkin.
Mild ubiquitination of PDCD2-1 was noted without transfection of
3XMyc-parkin (lane 3, Fig. 2A–C). These results may reﬂect the
inﬂuence of endogenous parkin in COS1 cells. To examine whether
parkin promotes PDCD2-1 degradation, COS1 cells were transfec-
ted with a ﬁxed amount of 3XFLAG-PDCD2-1 and increasing
amounts of 3XMyc-parkin. The total amounts of transfected plas-
mids were adjusted with 3XMyc plasmid to avoid the inﬂuenceFig. 3. Degradation of PDCD2 depends on parkin. (A) Lysates prepared from COS1
cells transfected with 3XFLAG-PDCD2-1 and with 3XMyc-parkin. The amount of
transfected 3XFLAG-PDCD2-1 was ﬁxed at 1 lg while the amount of transfected
3XMyc-parkin was increased to 0, 3, 6, and 9 lg. The total amounts of transfected
plasmids were adjusted with 3XMyc plasmid to avoid the inﬂuence of transfection.
(B) Data are expressed as mean ± S.E.M. Note the fall in the level of 3XFLAG-PDCD2-
1 with increased expression of 3XMyc-parkin.of transfection, and the experiment was performed three times.
As is shown in Fig. 3A and B, the amount of co-transfected parkin
modulated the level of PDCD2-1 in a dose-dependent manner;
the relative value of PDCD2-1 decreased to approximately 60% at
the highest dose of parkin.
3.4. Accumulation of PDCD2 in SN of ARPD and sPD
In the next step, we examined the level of PDCD2-1 in the SN of
patients with ARPD and sPD and control subjects. The brain tissues
were homogenized followed by western blotting with rabbit poly-
clonal anti-PDCD2 antibody. As shown Fig. 4A–C, the amount of
PDCD2-1 was higher in all ARPD and sPD compared with the con-
trol subjects. Furthermore, PDCD2-1 level was lower in Cases 2 and
5 with high amount of parkin, compared with those with low
amount of parkin Fig. 4A–C.
We demonstrated in the present study that PDCD2-1 is a parkin
substrate. PDCD2-1 is expressed ubiquitously in various human
tissues including the brain [4]. Previous reports described the
involvement of PDCD2-1 in various processes such as apoptosis,
inﬂammation, and cell proliferation [6,8–10]. Although the role
of PDCD2-1 in the central nervous system remains to be elucidated,
the expression of Rp-8, which is homologous to PDCD2-1, increases
during cell death in rodent cerebellum [5]. Furthermore, antisense
knockdown of parkin causes apoptosis of SH-SY5Y cells [11] and
overexpression of parkin protects SH-SY5Y cells against apoptosisFig. 4. (A) Quantitative analysis of PDCD2-1 and parkin levels normalized to
GAPDH in control subjects, sPD, and ARPD. Homogenates of human midbrain from
control subjects (n = 3), sPD (n = 3), and ARPD (n = 3) were immunoblotted with
anti-PDCD2 (top panel) and anti-parkin (middle panel) antibodies. (B) PDCD2-1
levels were signiﬁcantly higher in sPD and ARPD than control subjects. The levels of
PDCD2-1 in the SN of sPD and ARPD were 2.2 to 5.1- and 3.8 to 5.7-fold higher than
the control, respectively. (C) Expression of parkin was noted in control and sPD, but
not in ARPD.
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suggest that parkin is associated with apoptosis and its anti-
apoptotic protective effect is dependent on its E3 activity.
Another important ﬁnding of this study was the increased levels
of PDCD2-1 in the SN of ARPD and sPD. To date, several studies
demonstrated that parkin is modiﬁed after translation [13,14].
Both in vivo and in vitro experiments have shown that parkin is
s-nitrosylated and that such s-nitrosylation serves to inhibit the
E3 ligase activity and protective function of parkin [13,14]. Fur-
thermore, s-nitrosylated parkin is increased in sPD [13,14]. These
results suggest the pathogenesis of sPD could also involve failure
of parkin activity in the UPS. The UPS may be an important and
common pathway of nigral neuronal death in both ARPD and sPD.
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